Obesity Management

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Luke Turnock, PhD, MSc, discussed current trends in the promotion of lifestyle enhancement drugs for populations they are not approved for.

One asymptomatic patient did experience drug-induced liver injury that was resolved after discontinuation of danuglipron.

Investigators find 5 distinct obesity trajectories that influenced brain morphology, function, and cognition.

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

The outpatient endoscopic procedure modifies duodenal dysfunction and restores metabolic health.

Lydia Newsom, PharmD, discusses injection techniques, managing side effects, and the importance of collaboration between the healthcare team.

Lydia Newsom, PharmD, discuses how pharmacists can support patients using GLP-1s.

Researchers explored how social media advertising of lifestyle drugs contributes to the normalization of use for semaglutide, testosterone, and sildenafil.

On both an individual and societal level, researchers explored how social, cultural, and ethnic determinants impact the treatment and management of obesity.

Tirzepatide and semaglutide show long-term health care cost savings but, the high cost of the medications offset the savings.

Among various weights and diabetes diagnoses, researchers explored the differences in patients’ food perceptions when considering weight management and appetite.

Researchers compared changes in diet quality and waist-to-hip ratio during midlife with that of hippocampal connectivity and cognitive function in later life.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Among postmenopausal women, researchers explored associations between intentional weight loss and waist circumference (WC) reduction and mortality.

Researchers analyzed the association between adherence to a Mediterranean diet and obesity cancers, with a focus on the mediating role adiposity plays throughout the process.

All dosages of semaglutide (Wegovy) under the new program will be available at $499 per month for patients that are uninsured or who do not have coverage for obesity medication.

“The Commission reinforces that obesity is a disease and not due to lack of motivation, willpower, discipline, or laziness,” Robert F. Kushner said.

Researchers determined the prevalence of weight management interventions among patients who were obese and received an obstructive sleep apnea diagnosis.

The announcement comes after the FDA declared the shortage of semaglutide (Ozempic, Wegovy) has been resolved after being in shortage since March 2022.

The results of this study show that the concurrent presence of asthma and obesity did not synergistically amplify inflammation in children with both asthma and overweight/obesity.

Semaglutide has been in shortage since 2022 due to increased demand.

Tirzepatide (Mounjaro, Zepbound), a glucagon-like peptide-1 (GLP-1) medication, demonstrates improved diabetes control and decreases in insulin requirements.

ASC30, an investigational glucagon-like 1-peptide receptor agonist, demonstrates mean weight reductions from baseline of 4.3% and 6.3% for 2 separate cohorts.

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access to drugs that the organization had reviewed for cost effectiveness in 2022.

For weight loss and antihypertensive effects on systolic and diastolic blood pressure, semaglutide also had increased effects.

Recently, there has been concern around glucagon-like peptide-1 receptor agonists and increase the risk of thyroid cancer, with liraglutide having a black box warning label for the disease.

Researchers addressed the factors leading to and the rates of discontinuation and reinitiation of GLP-1 RAs among adults with obesity.

In a phase 1b/2a clinical trial, investigators evaluated the once weekly subcutaneous drug for safety, tolerability, pharmacokinetics, and proof-of-concept.

Taking once-weekly subcutaneous semaglutide does not increase depression symptoms or suicidal ideation in patients with obesity.